Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1923 1
1950 4
1951 6
1952 5
1953 2
1954 2
1955 6
1957 2
1958 1
1959 2
1960 4
1961 8
1962 16
1963 16
1964 18
1965 12
1966 18
1967 32
1968 27
1969 38
1970 19
1971 25
1972 29
1973 34
1974 41
1975 39
1976 46
1977 35
1978 49
1979 36
1980 58
1981 58
1982 57
1983 83
1984 80
1985 84
1986 83
1987 90
1988 76
1989 106
1990 103
1991 135
1992 128
1993 177
1994 171
1995 175
1996 181
1997 198
1998 219
1999 220
2000 219
2001 219
2002 264
2003 254
2004 248
2005 235
2006 280
2007 305
2008 322
2009 291
2010 299
2011 362
2012 340
2013 419
2014 413
2015 430
2016 427
2017 445
2018 431
2019 455
2020 524
2021 606
2022 612
2023 491
2024 552
2025 455

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

11,737 results

Results by year

Filters applied: . Clear all
Page 1
Patritumab Deruxtecan (HER3-DXd), a Human Epidermal Growth Factor Receptor 3-Directed Antibody-Drug Conjugate, in Patients With Previously Treated Human Epidermal Growth Factor Receptor 3-Expressing Metastatic Breast Cancer: A Multicenter, Phase I/II Trial.
Krop IE, Masuda N, Mukohara T, Takahashi S, Nakayama T, Inoue K, Iwata H, Yamamoto Y, Alvarez RH, Toyama T, Takahashi M, Osaki A, Saji S, Sagara Y, O'Shaughnessy J, Ohwada S, Koyama K, Inoue T, Li L, Patel P, Mostillo J, Tanaka Y, Sternberg DW, Sellami D, Yonemori K. Krop IE, et al. Among authors: takahashi s. J Clin Oncol. 2023 Dec 20;41(36):5550-5560. doi: 10.1200/JCO.23.00882. Epub 2023 Oct 6. J Clin Oncol. 2023. PMID: 37801674 Free PMC article. Clinical Trial.
Vaccine Therapy for Heart Failure Targeting the Inflammatory Cytokine Igfbp7.
Katoh M, Nomura S, Yamada S, Ito M, Hayashi H, Katagiri M, Heryed T, Fujiwara T, Takeda N, Nishida M, Sugaya M, Kato M, Osawa T, Abe H, Sakurai Y, Ko T, Fujita K, Zhang B, Hatsuse S, Yamada T, Inoue S, Dai Z, Kubota M, Sawami K, Ono M, Morita H, Kubota Y, Mizuno S, Takahashi S, Nakanishi M, Ushiku T, Nakagami H, Aburatani H, Komuro I. Katoh M, et al. Among authors: takahashi s. Circulation. 2024 Jul 30;150(5):374-389. doi: 10.1161/CIRCULATIONAHA.123.064719. Epub 2024 Jul 11. Circulation. 2024. PMID: 38991046
Landscape of driver mutations and their clinical effects on Down syndrome-related myeloid neoplasms.
Sato T, Yoshida K, Toki T, Kanezaki R, Terui K, Saiki R, Ojima M, Ochi Y, Mizuno S, Yoshihara M, Uechi T, Kenmochi N, Tanaka S, Matsubayashi J, Kisai K, Kudo K, Yuzawa K, Takahashi Y, Tanaka T, Yamamoto Y, Kobayashi A, Kamio T, Sasaki S, Shiraishi Y, Chiba K, Tanaka H, Muramatsu H, Hama A, Hasegawa D, Sato A, Koh K, Karakawa S, Kobayashi M, Hara J, Taneyama Y, Imai C, Hasegawa D, Fujita N, Yoshitomi M, Iwamoto S, Yamato G, Saida S, Kiyokawa N, Deguchi T, Ito M, Matsuo H, Adachi S, Hayashi Y, Taga T, Saito AM, Horibe K, Watanabe K, Tomizawa D, Miyano S, Takahashi S, Ogawa S, Ito E. Sato T, et al. Among authors: takahashi s. Blood. 2024 Jun 20;143(25):2627-2643. doi: 10.1182/blood.2023022247. Blood. 2024. PMID: 38513239 Free article.
Microbiota dictate T cell clonal selection to augment graft-versus-host disease after stem cell transplantation.
Yeh AC, Koyama M, Waltner OG, Minnie SA, Boiko JR, Shabaneh TB, Takahashi S, Zhang P, Ensbey KS, Schmidt CR, Legg SRW, Sekiguchi T, Nelson E, Bhise SS, Stevens AR, Goodpaster T, Chakka S, Furlan SN, Markey KA, Bleakley ME, Elson CO, Bradley PH, Hill GR. Yeh AC, et al. Among authors: takahashi s. Immunity. 2024 Jul 9;57(7):1648-1664.e9. doi: 10.1016/j.immuni.2024.05.018. Epub 2024 Jun 13. Immunity. 2024. PMID: 38876098 Free PMC article.
Wnt-deficient and hypoxic environment orchestrates squamous reprogramming of human pancreatic ductal adenocarcinoma.
Tamagawa H, Fujii M, Togasaki K, Seino T, Kawasaki S, Takano A, Toshimitsu K, Takahashi S, Ohta Y, Matano M, Kawasaki K, Machida Y, Sekine S, Machinaga A, Sasai K, Kodama Y, Kakiuchi N, Ogawa S, Hirano T, Seno H, Kitago M, Kitagawa Y, Iwasaki E, Kanai T, Sato T. Tamagawa H, et al. Among authors: takahashi s. Nat Cell Biol. 2024 Oct;26(10):1759-1772. doi: 10.1038/s41556-024-01498-5. Epub 2024 Sep 4. Nat Cell Biol. 2024. PMID: 39232216
Basal-shift transformation leads to EGFR therapy-resistance in human lung adenocarcinoma.
Shinozaki T, Togasaki K, Hamamoto J, Mitsuishi A, Fukushima T, Sugihara K, Ebisudani T, Okada M, Saito A, Shigematsu L, Takaoka H, Ito F, Ohgino K, Ishioka K, Watanabe K, Hishima T, Kurebayashi Y, Emoto K, Terai H, Ikemura S, Kawada I, Asakura K, Hishida T, Asamura H, Ohta Y, Takahashi S, Oda M, Saito M, Matano M, Soejima K, Fujii M, Fukunaga K, Yasuda H, Sato T. Shinozaki T, et al. Among authors: takahashi s. Nat Commun. 2025 May 11;16(1):4369. doi: 10.1038/s41467-025-59623-3. Nat Commun. 2025. PMID: 40350470 Free PMC article.
The Whole Picture of First-Line Osimertinib for EGFR Mutation-Positive Advanced NSCLC: Real-World Efficacy, Safety, Progression Pattern, and Posttreatment Therapy (Reiwa Study).
Watanabe K, Hosomi Y, Naoki K, Nakahara Y, Tsukita Y, Matsumoto H, Yoh K, Fujisaka Y, Takahashi S, Takata S, Usui K, Kishi K, Naka G, Tamano S, Uemura K, Kunitoh H. Watanabe K, et al. Among authors: takahashi s. JTO Clin Res Rep. 2024 Sep 7;5(11):100720. doi: 10.1016/j.jtocrr.2024.100720. eCollection 2024 Nov. JTO Clin Res Rep. 2024. PMID: 39416709 Free PMC article.
11,737 results
You have reached the last available page of results. Please see the User Guide for more information.